Hepalife 300 Tablet contains Ursodeoxycholic Acid 300 mg, a hydrophilic bile acid used primarily for the treatment of various hepatobiliary disorders. Ursodeoxycholic Acid acts by reducing the cholesterol content of bile and bile stones, promoting bile flow, and protecting hepatocytes against cytotoxicity induced by hydrophobic bile acids. It is indicated in the management of primary biliary cholangitis, dissolution of cholesterol gallstones in patients who are not candidates for surgery, and certain cholestatic liver diseases. Hepalife 300 is also utilized to improve liver function tests and alleviate symptoms associated with cholestasis. The drug is generally well tolerated, with side effects such as diarrhea, abdominal discomfort, and nausea being relatively uncommon. It should be administered under medical supervision with dosage adjustments based on clinical response and liver function tests. Contraindications include complete biliary obstruction, acute inflammation of the gallbladder or bile ducts, and hypersensitivity to Ursodeoxycholic Acid. Hepalife 300 Tablet offers a targeted therapeutic approach to improve bile composition, enhance hepatic function, and support the management of chronic liver conditions, thereby contributing to improved patient outcomes in hepatobiliary diseases.